Search | Search by Center | Search by Source | Keywords in Title
Mafi JN, Leng M, Arbanas JC, Tseng CH, Damberg CL, Sarkisian C, Landon BE. Estimated Annual Spending on Aducanumab in the US Medicare Program. JAMA health forum. 2022 Jan 1; 3(1):e214495.
This cross-sectional study examines upper bound and lower bound annualized Medicare costs for administering aducanumab to beneficiaries with the approved indications of mild cognitive impairment or mild dementia.